Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
44
HOCPF Quote, Financials, Valuation and Earnings
Last price:
$153.73
Seasonality move
:
-1.24%
Day range:
$143.58 - $143.58
52-week range:
$96.42 - $167.52
Dividend yield:
1.12%
P/E ratio:
35.20x
P/S ratio:
8.26x
P/B ratio:
7.17x
Volume:
158
Avg. volume:
236
1-year change:
17.59%
Market cap:
$48.9B
Revenue:
$5.7B
EPS (TTM):
$4.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HOCPF
HOYA Corp.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 3.82% | -- | $17.93 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HOCPF
HOYA Corp.
|
$143.58 | -- | $48.9B | 35.20x | $0.84 | 1.12% | 8.26x |
|
HLOSF
Healios KK
|
$1.93 | -- | $222.8M | -- | $0.00 | 0% | 303.04x |
|
PPTDF
PeptiDream Inc.
|
$12.48 | -- | $1.6B | 13.79x | $0.00 | 0% | 13.44x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.48 | -- | $495.9M | -- | $0.00 | 0% | 2.56x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$15.69 | $17.93 | $49.6B | 199.11x | $0.32 | 4.21% | 1.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HOCPF
HOYA Corp.
|
3.97% | 1.357 | 0.61% | 4.06x |
|
HLOSF
Healios KK
|
47.23% | -0.711 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.120 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.139 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.844 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HOCPF
HOYA Corp.
|
$1.3B | $461M | 20.27% | 21.03% | 29% | $395.2M |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
HOYA Corp. vs. Competitors
-
Which has Higher Returns HOCPF or HLOSF?
Healios KK has a net margin of 23.44% compared to HOYA Corp.'s net margin of -9751.87%. HOYA Corp.'s return on equity of 21.03% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital HOCPFHOYA Corp.79.54% $1.10 $7.1B HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About HOCPF or HLOSF?
HOYA Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that HOYA Corp. has higher upside potential than Healios KK, analysts believe HOYA Corp. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings HOCPFHOYA Corp.0 0 0 HLOSFHealios KK0 0 0 -
Is HOCPF or HLOSF More Risky?
HOYA Corp. has a beta of 1.014, which suggesting that the stock is 1.422% more volatile than S&P 500. In comparison Healios KK has a beta of 0.260, suggesting its less volatile than the S&P 500 by 73.986%.
-
Which is a Better Dividend Stock HOCPF or HLOSF?
HOYA Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 1.12%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOYA Corp. pays 27.52% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. HOYA Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HOCPF or HLOSF?
HOYA Corp. quarterly revenues are $1.6B, which are larger than Healios KK quarterly revenues of $128.8K. HOYA Corp.'s net income of $372.7M is higher than Healios KK's net income of $3.8M. Notably, HOYA Corp.'s price-to-earnings ratio is 35.20x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOYA Corp. is 8.26x versus 303.04x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOCPFHOYA Corp.8.26x 35.20x $1.6B $372.7M HLOSFHealios KK303.04x -- $128.8K $3.8M
-
Which has Higher Returns HOCPF or PPTDF?
PeptiDream Inc. has a net margin of 23.44% compared to HOYA Corp.'s net margin of -25.38%. HOYA Corp.'s return on equity of 21.03% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital HOCPFHOYA Corp.79.54% $1.10 $7.1B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About HOCPF or PPTDF?
HOYA Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that HOYA Corp. has higher upside potential than PeptiDream Inc., analysts believe HOYA Corp. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOCPFHOYA Corp.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is HOCPF or PPTDF More Risky?
HOYA Corp. has a beta of 1.014, which suggesting that the stock is 1.422% more volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.551, suggesting its less volatile than the S&P 500 by 44.854%.
-
Which is a Better Dividend Stock HOCPF or PPTDF?
HOYA Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 1.12%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOYA Corp. pays 27.52% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. HOYA Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HOCPF or PPTDF?
HOYA Corp. quarterly revenues are $1.6B, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. HOYA Corp.'s net income of $372.7M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, HOYA Corp.'s price-to-earnings ratio is 35.20x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOYA Corp. is 8.26x versus 13.44x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOCPFHOYA Corp.8.26x 35.20x $1.6B $372.7M PPTDFPeptiDream Inc.13.44x 13.79x $29.3M -$7.4M
-
Which has Higher Returns HOCPF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 23.44% compared to HOYA Corp.'s net margin of -24.76%. HOYA Corp.'s return on equity of 21.03% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital HOCPFHOYA Corp.79.54% $1.10 $7.1B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About HOCPF or SOLTF?
HOYA Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that HOYA Corp. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe HOYA Corp. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HOCPFHOYA Corp.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is HOCPF or SOLTF More Risky?
HOYA Corp. has a beta of 1.014, which suggesting that the stock is 1.422% more volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.011, suggesting its less volatile than the S&P 500 by 98.941%.
-
Which is a Better Dividend Stock HOCPF or SOLTF?
HOYA Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 1.12%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOYA Corp. pays 27.52% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. HOYA Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HOCPF or SOLTF?
HOYA Corp. quarterly revenues are $1.6B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. HOYA Corp.'s net income of $372.7M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, HOYA Corp.'s price-to-earnings ratio is 35.20x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOYA Corp. is 8.26x versus 2.56x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOCPFHOYA Corp.8.26x 35.20x $1.6B $372.7M SOLTFNxera Pharma Co., Ltd.2.56x -- $45.8M -$11.3M
-
Which has Higher Returns HOCPF or STMM?
Stemcell Holdings, Inc. has a net margin of 23.44% compared to HOYA Corp.'s net margin of --. HOYA Corp.'s return on equity of 21.03% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HOCPFHOYA Corp.79.54% $1.10 $7.1B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About HOCPF or STMM?
HOYA Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that HOYA Corp. has higher upside potential than Stemcell Holdings, Inc., analysts believe HOYA Corp. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOCPFHOYA Corp.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is HOCPF or STMM More Risky?
HOYA Corp. has a beta of 1.014, which suggesting that the stock is 1.422% more volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HOCPF or STMM?
HOYA Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 1.12%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOYA Corp. pays 27.52% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. HOYA Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HOCPF or STMM?
HOYA Corp. quarterly revenues are $1.6B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. HOYA Corp.'s net income of $372.7M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, HOYA Corp.'s price-to-earnings ratio is 35.20x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOYA Corp. is 8.26x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOCPFHOYA Corp.8.26x 35.20x $1.6B $372.7M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns HOCPF or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of 23.44% compared to HOYA Corp.'s net margin of -1.05%. HOYA Corp.'s return on equity of 21.03% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital HOCPFHOYA Corp.79.54% $1.10 $7.1B TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About HOCPF or TAK?
HOYA Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.93 which suggests that it could grow by 14.14%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than HOYA Corp., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than HOYA Corp..
Company Buy Ratings Hold Ratings Sell Ratings HOCPFHOYA Corp.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is HOCPF or TAK More Risky?
HOYA Corp. has a beta of 1.014, which suggesting that the stock is 1.422% more volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.019, suggesting its less volatile than the S&P 500 by 98.068%.
-
Which is a Better Dividend Stock HOCPF or TAK?
HOYA Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 1.12%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.21% to investors and pays a quarterly dividend of $0.32 per share. HOYA Corp. pays 27.52% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. HOYA Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios HOCPF or TAK?
HOYA Corp. quarterly revenues are $1.6B, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. HOYA Corp.'s net income of $372.7M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, HOYA Corp.'s price-to-earnings ratio is 35.20x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 199.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOYA Corp. is 8.26x versus 1.69x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOCPFHOYA Corp.8.26x 35.20x $1.6B $372.7M TAKTakeda Pharmaceutical Co., Ltd.1.69x 199.11x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
